Organon & Co. (NYSE:OGN) & Merck & Co., Inc. (NYSE:MRK) Head to Head Review

Organon & Co. (NYSE:OGN – Get Free Report) and Merck & Co., Inc. (NYSE:MRK – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.

Profitability

This table compares Organon & Co. and Merck & Co., Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Organon & Co. 3.49% 82.06% 6.03%
Merck & Co., Inc. 3.64% 16.73% 5.88%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Organon & Co. and Merck & Co., Inc., as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organon & Co. 1 4 0 0 1.80
Merck & Co., Inc. 1 11 16 1 2.59

Organon & Co. presently has a consensus price target of $12.00, suggesting a potential downside of 13.76%. Merck & Co., Inc. has a consensus price target of $155.74, suggesting a potential upside of 13.06%. Given Merck & Co., Inc.’s stronger consensus rating and higher possible upside, analysts plainly believe Merck & Co., Inc. is more favorable than Organon & Co..

Valuation and Earnings

This table compares Organon & Co. and Merck & Co., Inc.”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Organon & Co. $6.22 billion 0.59 $187.00 million $0.76 18.31
Merck & Co., Inc. $65.01 billion 5.22 $18.25 billion $0.97 142.01

Merck & Co., Inc. has higher revenue and earnings than Organon & Co.. Organon & Co. is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Dividends

Organon & Co. pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 2.5%. Organon & Co. pays out 10.5% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 350.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has raised its dividend for 14 consecutive years. Merck & Co., Inc. is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Risk and Volatility

Organon & Co. has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500.

Insider & Institutional Ownership

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by company insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Merck & Co., Inc. beats Organon & Co. on 12 of the 18 factors compared between the two stocks.

About Organon & Co.

(Get Free Report)

Organon & Co. is a global health care company focused on women’s health, biosimilars and established medicines. It develops and markets prescription medicines and other health products for patients and health care professionals. Its women’s health portfolio includes contraceptive and fertility products, while its biosimilars business offers biologic medicines in areas such as immunology and oncology. The company also sells established medicines across several therapeutic areas, including cardiovascular health, respiratory conditions and dermatology.

About Merck & Co., Inc.

(Get Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.